No headlines found.
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Globe Newswire (Wed, 10-Dec 9:00 AM ET)
AIM ImmunoTech to Participate in Live 'Fireside' Chat on Virtual Investor Closing Bell Series
Globe Newswire (Mon, 1-Dec 8:55 AM ET)
Globe Newswire (Tue, 18-Nov 8:55 AM ET)
Globe Newswire (Mon, 10-Nov 8:55 AM ET)
Globe Newswire (Tue, 4-Nov 9:05 AM ET)
Globe Newswire (Mon, 3-Nov 8:55 AM ET)
AIM ImmunoTech to Attend the 2025 Maxim Growth Summit
Globe Newswire (Mon, 20-Oct 9:15 AM ET)
Globe Newswire (Thu, 25-Sep 8:45 AM ET)
Globe Newswire (Mon, 22-Sep 9:00 AM ET)
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
Aim Immunotech trades on the AMEX stock market under the symbol AIM.
As of December 10, 2025, AIM stock price declined to $1.46 with 8,486 million shares trading.
AIM has a beta of 7.10, meaning it tends to be more sensitive to market movements. AIM has a correlation of 0.24 to the broad based SPY ETF.
AIM has a market cap of $4.17 million. This is considered a Sub-Micro Cap stock.
AIM support price is $1.38 and resistance is $1.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AIM shares will trade within this expected range on the day.
